Ko patiesībā atklāja GLP-1 izmēģinājumi

Nav pirms un pēc, nav ietekmētāju. Tikai randomizētie izmēģinājumi, efekta lielumi un daļas, ko mārketings atstāj novārtā — katrs apgalvojums saistīts ar tā PubMed ierakstu.

66peer-reviewed citations
42European languages
0sponsored verdicts
Injekciju pildspalva, kas turēta pret ādas portu uz apakšdelma.
Marius Vassnes · CC BY-SA 4.0 · Wikimedia Commons

Start here

Each page answers one question and shows its working. If you only read one, read the page on stopping — it is the finding that changes how you should think about the whole class.

Mechanism

How GLP-1 drugs actually work

Slower gastric emptying, hypothalamic satiety signalling, and why "it just makes you eat less" is both true and incomplete.

Body composition

How much of the loss is muscle?

Roughly a quarter to a third of the weight lost is lean mass. Whether that matters is a harder question.

Durability

What happens when you stop

Most of the weight comes back within a year. This is the single most important finding in the field.

Outcomes

Does it protect your heart?

SELECT found a 20% reduction in major cardiovascular events — in a population that was not diabetic.

Pipeline

The oral pills

Oral semaglutide and orforglipron: same class, no needle, slightly smaller effect.

Saistītā literatūra

Fasting Evidence

Intermittent fasting, time-restricted eating and meal timing, judged on the trial data.

Metabolism Review

Energy expenditure, insulin resistance and metabolic adaptation, without the folklore.

Weight Loss Evidence

Diets, drugs, behaviour and maintenance — ranked by the strength of the evidence behind them.

Sleep Evidence

Sleep, circadian rhythm and the wearables that claim to measure both.

Šī lapa tika automātiski tulkota no angļu valodas. Atsauces un skaitļi paliek nemainīgi. Izlasiet angļu oriģinālu, ja kaut kas šķiet dīvaini. Izlasīt angļu oriģinālu